Navigation Links
GeoVax to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:8/26/2009

& Renshaw Capital Group, Inc., will hold its Annual Global Investment Conference from September 9-11, 2009 at the New York Palace Hotel, New York City. The Conference will feature tracks devoted to Healthcare, Metals & Mining, Energy, Cleantech, Asia, Community & Regional Banks, Growth, & Maritime. More than 500 public & private companies have already registered to present at this year's conference. Over 2,500 conference attendees are expected including institutional investors, venture capitalists, sophisticated private investors, business development/partnering executives, members of private equity firms, and other experts from the worldwide medical and research communities.

HIV/AIDS Background

HIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide. Presently, there is little to prevent HIV transmission other than education, circumcision, and condoms. It is obvious from the spread of the disease that these methods are not adequate. Existing treatments for individuals infected with HIV include anti-retroviral therapies that are effective but have serious medical side effects and are expensive (upwards of $1,500/month). This cost is borne primarily by the individual and sometimes by third party insurance, local healthcare, federal or world health organizations. Development and distribution of an effective HIV/AIDS vaccine holds great promise. The GeoVax Vaccine would cost a fraction of the cost of current treatments and, to date, has not elicited serious adverse side effects in several human trials. A population vaccinated with an effective H
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVax to Present at the BIO CEO & Investor Conference 2009
10. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
11. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... , Trial conducted pursuant to Special ... QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... global biopharmaceutical company focused on oncology and endocrine therapy, ... Inc. ("Keryx") ( KERX), of a Phase 3 registration ...
... , , , ... for Nanosphere, Inc.,s Verigene(R) and Verigene(R) SP systems for,infringement of ... the,identification and/or the quantification of a target compound". The import,ban ... any country of,the European Union. Customs authorities are required to ...
... ... will hold its 23rd Annual Technical Conference & Exhibition on March 22-25, 2010 at the ... out to even more experts in the field we are proud to announce that the ... , , ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2American Filtration and Separations Society to Hold 23nd Annual Technical Conference 2American Filtration and Separations Society to Hold 23nd Annual Technical Conference 3American Filtration and Separations Society to Hold 23nd Annual Technical Conference 4
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... and can quickly become life threatening for some children.    ... as 1.2 million Canadians have food allergies and this number ... cent of children are estimated to have food allergies.  ... mild skin irritations and hives to breathing difficulties and loss ...
(Date:8/20/2014)... visible in in this image of the Para and ... were most likely intentionally set in order to deforest ... or stand of trees where the land is thereafter ... conversion of forestland to farms, ranches, or urban use. ... of the Amazon Rainforest in the middle of the ...
(Date:8/20/2014)... Calif., August 19, 2014 -- Bay Area Lyme Foundation, ... and simple to cure, applauds new research published in ... Ticks and Tick-borne Diseases . The findings ... California are active throughout the year, making the threat ... researchers at California Department of Public Health (CDPH) Vector-borne ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... the Olympic Peninsula joined in an exceptional partnership with ... Washington to develop a set of science-based options that ... sustainability in the face of a changing climate. ... roads, fish, and wildlife on the peninsulaare published in ...
... of their offspring so they inherit either their mother,s ... more offspring are more likely to have daughters. ... successful, produce more sons. The study, by scientists ... Kyushu University (Japan), is published today (9 January) in ...
... University of Utah biology Professor Nalini Nadkarni is being ... the American Association for the Advancement of Science (AAAS) ... Award. The AAAS has issued the news release below: ... (AAAS) has named Nalini M. Nadkarni as the recipient ...
Cached Biology News:Partnership yields options for adapting to climate change on the Olympic Peninsula 2Fit females make more daughters, mighty males get grandsons 2Utah biologist wins 2011 AAAS Public Engagement with Science Award 2Utah biologist wins 2011 AAAS Public Engagement with Science Award 3
MOUSE ANTI POLY (ADP-RIBOSE) Immunogen: Purified poly (ADP-ribose) polymer, 10-50 unit chain length...
... by N.C. Price (1996) • ... on protein chemistry and the ... proteins. Data on the following ... size determination, amino acid analysis ...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
...
Biology Products: